SRPT vs. TAK, ARGX, BNTX, TEVA, BGNE, SMMT, GMAB, VTRS, ITCI, and MRNA
Should you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include Takeda Pharmaceutical (TAK), argenx (ARGX), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Intra-Cellular Therapies (ITCI), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.
Sarepta Therapeutics vs.
Sarepta Therapeutics (NASDAQ:SRPT) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, community ranking, dividends and analyst recommendations.
In the previous week, Sarepta Therapeutics had 20 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 22 mentions for Sarepta Therapeutics and 2 mentions for Takeda Pharmaceutical. Sarepta Therapeutics' average media sentiment score of 0.75 beat Takeda Pharmaceutical's score of 0.58 indicating that Sarepta Therapeutics is being referred to more favorably in the media.
86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 7.7% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Sarepta Therapeutics currently has a consensus price target of $178.71, indicating a potential upside of 53.94%. Given Sarepta Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sarepta Therapeutics is more favorable than Takeda Pharmaceutical.
Sarepta Therapeutics has a net margin of 7.43% compared to Takeda Pharmaceutical's net margin of 6.49%. Sarepta Therapeutics' return on equity of 11.00% beat Takeda Pharmaceutical's return on equity.
Sarepta Therapeutics received 1363 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 75.33% of users gave Sarepta Therapeutics an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.
Sarepta Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.
Takeda Pharmaceutical has higher revenue and earnings than Sarepta Therapeutics. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Sarepta Therapeutics beats Takeda Pharmaceutical on 16 of the 19 factors compared between the two stocks.
Get Sarepta Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sarepta Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SRPT) was last updated on 1/22/2025 by MarketBeat.com Staff
